Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
Top Cited Papers
Open Access
- 24 August 2017
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 130 (8), 974-981
- https://doi.org/10.1182/blood-2017-05-785246
Abstract
Key Points. No new safety signals were observed with daratumumab plus pomalidomide and dexamethasone, except for increased neutropenia.Daratumumab plus pomalidKeywords
This publication has 25 references indexed in Scilit:
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine, 2016
- Daratumumab, Bortezomib, and Dexamethasone for Multiple MyelomaNew England Journal of Medicine, 2016
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myelomaBlood, 2016
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myelomaBlood, 2016
- Effect of IMiD compounds on CD38 expression on multiple myeloma cells: MOR202, a human CD38 antibody in combination with pomalidomide.Journal of Clinical Oncology, 2015
- Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myelomamAbs, 2015
- Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 studyBlood, 2014
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2013
- Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyLeukemia, 2011
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological TumorsPublished by The American Association of Immunologists ,2011